Tenderwize
Retour à la recherche

Open-house rebate agreement for Aflibercept (excluding 114.3 mg/ml)

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 03, 2027 · 431 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aflibercept, ausgenommen 114,3 mg/ml, ATC S01LA05

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The notice uses an open-house model while the form type is 'open'; although the buyer explains this, the procedural fra...

Paper submissions are only timely if the scan is sent in advance and the original paper documents arrive by the 10th of...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Non-exclusive rebate agreements for the medicinal product Aflibercept, excluding 114.3 mg/ml, ATC S01LA05.
  • Supply contract for pharmaceutical products under an open-house model.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement by AOK Bayern for Aflibercept (excluding 114.3 mg/ml, ATC S01LA05). It is not a competitive award procedure in the usual sense: the buyer states that any pharmaceutical company meeting the stated suitability requirement can join on identical, non-negotiable terms. The contract period runs from 2026-01-01 to 2027-12-31, with contract entry possible until 2027-11-03. Submission is via DTVP electronic portal with qualified electronic signature or by signed paper originals in duplicate. No contract value is stated.

Risques

The notice uses an open-house model while the form type is 'open'; although the buyer explains this, the procedural fra...

Paper submissions are only timely if the scan is sent in advance and the original paper documents arrive by the 10th of...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Aflibercept (excluding 114.3 mg/ml)

Open-house supply arrangement for pharmaceutical rebate agreements concerning Aflibercept, excluding 114.3 mg/ml, ATC S01LA05. The lot is described as a non-exclusive, identical, non-individually negotiable contract offered to all interested pharmaceutical companies meeting the suitability requirement. Source: structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Dec 2025 - Dec 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 03, 2027

Détails de la procédure

Date de publication
16 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
760140-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30